TY - JOUR
T1 - Cardiovascular health during and after cancer therapy
AU - Ruddy, Kathryn J.
AU - Patel, Shruti R.
AU - Higgins, Alexandra S.
AU - Armenian, Saro H.
AU - Herrmann, Joerg
N1 - Funding Information:
TACTIC R01 (K.J.R. and J.H.); Lymphoma & Leukemia Society Scholar Award (SA) R01 HL150069 (SA).
Publisher Copyright:
© 2020 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2020/12
Y1 - 2020/12
N2 - Certain cancer treatments have been linked to specific cardiovascular toxicities, including (but not limited to) cardiomyopathy, atrial fibrillation, arterial hypertension, and myocarditis. Radiation, anthracyclines, human epidermal growth factor receptor 2 (Her2)-directed therapies, fluoropyrimidines, platinums, tyrosine kinase inhibitors and proteasome inhibitors, immune checkpoint inhibitors, and chimeric antigen-presenting (CAR)-T cell therapy can all cause cardiovascular side effects. Management of cardiovascular dysfunction that occurs during cancer therapy often requires temporary or permanent cessation of the risk-potentiating anti-neoplastic drug as well as optimization of medical management from a cardiovascular standpoint. Stem cell or bone marrow transplant recipients face unique cardiovascular challenges, as do patients at extremes of age.
AB - Certain cancer treatments have been linked to specific cardiovascular toxicities, including (but not limited to) cardiomyopathy, atrial fibrillation, arterial hypertension, and myocarditis. Radiation, anthracyclines, human epidermal growth factor receptor 2 (Her2)-directed therapies, fluoropyrimidines, platinums, tyrosine kinase inhibitors and proteasome inhibitors, immune checkpoint inhibitors, and chimeric antigen-presenting (CAR)-T cell therapy can all cause cardiovascular side effects. Management of cardiovascular dysfunction that occurs during cancer therapy often requires temporary or permanent cessation of the risk-potentiating anti-neoplastic drug as well as optimization of medical management from a cardiovascular standpoint. Stem cell or bone marrow transplant recipients face unique cardiovascular challenges, as do patients at extremes of age.
KW - Anthracycline
KW - Cardio-oncology
KW - Congestive heart failure
KW - Myocarditis
UR - http://www.scopus.com/inward/record.url?scp=85097808925&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85097808925&partnerID=8YFLogxK
U2 - 10.3390/cancers12123737
DO - 10.3390/cancers12123737
M3 - Review article
AN - SCOPUS:85097808925
SN - 2072-6694
VL - 12
SP - 1
EP - 16
JO - Cancers
JF - Cancers
IS - 12
M1 - 3737
ER -